NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 132.05% | 131.17% | 132.94% | 25.07% | 26.34% |
| Total Depreciation and Amortization | -40.21% | -25.53% | -24.37% | 4.78% | -2.86% |
| Total Amortization of Deferred Charges | -93.97% | -90.10% | -76.96% | -48.28% | 28.87% |
| Total Other Non-Cash Items | -85.06% | -93.85% | -81.25% | -40.44% | -32.99% |
| Change in Net Operating Assets | 36.93% | -186.85% | 395.78% | 15.24% | -153.13% |
| Cash from Operations | 196.59% | 252.43% | 264.33% | 6.73% | 17.13% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | 89.47% | 68.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 100.00% | 89.47% | 68.75% |
| Total Debt Issued | -- | -- | -83.33% | -83.33% | -100.00% |
| Total Debt Repaid | 61.63% | 47.68% | 6.43% | -35.07% | -250.00% |
| Issuance of Common Stock | -76.81% | 341.59% | 558.23% | 449.56% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -99,350.00% | -99,350.00% | -855.50% | 36.46% | 99.32% |
| Cash from Financing | -377.60% | 141.73% | -70.45% | -21.52% | -80.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -78.64% | -59.74% | -57.58% | -57.58% | 301.37% |
| Net Change in Cash | 155.56% | 219.23% | 412.12% | -10.34% | -614.52% |